"WHO's Updated COVID Treatment Guidelines: Reducing Hospitalizations and Anticipating Future Surges"
The World Health Organization (WHO) has updated its guidelines for COVID-19 therapeutics, providing revised recommendations for patients with non-severe COVID-19. The update includes updated risk rates for hospital admission in patients with non-severe COVID-19, categorizing individuals into high, moderate, or low risk. WHO strongly recommends nirmatrelvir-ritonavir (Paxlovid) for high-risk and moderate-risk patients, with molnupiravir or remdesivir as alternatives if nirmatrelvir-ritonavir is unavailable. The use of ivermectin for non-severe COVID-19 is strongly advised against, while its use in severe or critical cases is limited to clinical trials.